| Authors: |
Landen CN; Department of Obstetrics and Gynecology, University of Virginia, Charlottesville, VA., Buckanovich RJ; UPMC Hillman Cancer Center and Magee-Womens Research Institute and Foundation, Pittsburgh, PA., Sill MW; Clinical Trials Development Division, NRG Oncology Statistical and Data Center, Roswell Park Comprehensive Cancer Center, Buffalo, NY., Mannel RS; University of Oklahoma Health Sciences, Stephenson Cancer Center, Oklahoma City, OK., Walker JL; University of Oklahoma Health Sciences, Stephenson Cancer Center, Oklahoma City, OK., DiSilvestro PA; Women & Infants Program in Women's Oncology, Providence, RI., Mathews CA; Women & Infants Program in Women's Oncology, Providence, RI., Mutch DG; Gynecologic Oncology, Washington University, St Louis, MO., Hernandez ML; Mercy Clinic Women's Oncology-Whiteside, Springfield, MO., Martin LP; Hospital of the University of Pennsylvania, Abramson Cancer Center, Philadelphia, PA., Bishop E; Froedtert & Medical College of Wisconsin, Milwaukee, WI., Gill SE; Gynecologic Oncology, SJC Oncology Services-Georgia, LLC, Savannah, GA., Gordinier ME; Norton Children's Hospital, Louisville, KY., Burger RA; Hospital of the University of Pennsylvania, Abramson Cancer Center, Philadelphia, PA.; Mersana Therapeutics, Cambridge, MA., Aghajanian C; Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY., Liu JF; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Moore KN; University of Oklahoma Health Sciences, Stephenson Cancer Center, Oklahoma City, OK., Bookman MA; Department of Medical Oncology, Kaiser-Permanente Northern California, San Francisco, CA. |
